Similar articles

• Request for the retraction of Cepp review 33: 504-510 (2006).

  Pushparaj P. Pushparaj P. Clin Exp Pharmacol Physiol. 2013 Apr;40(4):305. doi: 10.1111/1440-1681.12077. Clin Exp Pharmacol Physiol. 2013. PMID: 23551130 No abstract available.
• Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells.

  Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM. Ptasznik A, et al. Nat Med. 2004 Nov;10(11):1187-9. doi: 10.1038/nm1127. Epub 2004 Oct 24. Nat Med. 2004. PMID: 15502840
• RNA interference targeting of Bcr-Abl increases chronic myeloid leukemia cell killing by 17-allylamino-17-demethoxygeldanamycin.

  Withey JM, Harvey AJ, Crompton MR. Withey JM, et al. Leuk Res. 2006 May;30(5):553-60. doi: 10.1016/j.leukres.2005.09.013. Epub 2005 Nov 2. Leuk Res. 2006. PMID: 16260034
• Short interfering RNA (siRNA) as a novel therapeutic.

  Pushparaj PN, Melendez AJ. Pushparaj PN, et al. Clin Exp Pharmacol Physiol. 2006 May-Jun;33(5-6):504-10. doi: 10.1111/j.1440-1681.2006.04399.x. Clin Exp Pharmacol Physiol. 2006. Retraction in: Clin Exp Pharmacol Physiol. 2013 Apr;40(4):305. doi: 10.1111/1440-1681.12073. Retraction in: Clin Exp Pharmacol Physiol. 2013 Apr;40(4):305. doi: 10.1111/1440-1681.12075. PMID: 16700886 Retracted. Review.
• Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia.

  O'Dwyer ME, Druker BJ. O'Dwyer ME, et al. Curr Opin Oncol. 2000 Nov;12(6):594-7. doi: 10.1097/00001622-200011000-00013. Curr Opin Oncol. 2000. PMID: 11085460 Review.